FOLH1 and metastatic prostate carcinoma: Given the potential impact that 225Ac-PSMA-617 RLT could have on chemotherapy-naïve patients who presented late with advanced and aggressive disease, a prospective clinical trial is required to define the place of targeted alpha therapy with 225Ac-PSMA-617 in the management of metastatic prostate carcinoma and its relative efficacy compared with the currently approved therapy modalities.